Investigating how changes in blood vessel cells contribute to pulmonary hypertension
Endothelial Reprogramming in Pulmonary Hypertension
This study is looking at how certain proteins in the lungs affect blood vessel changes in pulmonary hypertension, with the hope of finding new ways to treat this serious condition and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10683075 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the pulmonary vascular endothelium in pulmonary hypertension (PH), a serious condition with limited treatment options. The study examines how specific proteins, particularly EBP50, influence the behavior of endothelial cells in the lungs and contribute to the disease's progression. By using both laboratory and animal models, the researchers aim to uncover the mechanisms behind vascular remodeling in PH and identify potential therapeutic targets. Patients may benefit from insights that could lead to new treatment strategies aimed at reversing the harmful changes in blood vessels associated with this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary hypertension who are seeking new treatment options.
Not a fit: Patients with pulmonary hypertension who have already exhausted all available treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reverse the vascular changes caused by pulmonary hypertension.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in other vascular diseases, suggesting potential for success in this area as well.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Al Ghouleh, Imad — University of Pittsburgh at Pittsburgh
- Study coordinator: Al Ghouleh, Imad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.